Gilead Secures Safety Advantage For TAF In HBV, Keeps Edge In HCV
This article was originally published in The Pink Sheet Daily
Top-line Phase III trials support transition plan from Viread. In hepatitis C, Gilead may be further strengthening its lead with a priority review for a pan-genotypic combo pill that replaces Harvoni's ledipasvir with a more potent NS5A inhibitor.
Register for our free email digests: